THY LAM: Open Payments
NPI 1083277255 · VISTA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$70,382 in 409 payments from 12 companies in 2025. Trend: 2023 $16,463 · 2024 $28,890 · 2025 $70,382
Speaker / faculty: $52,072Travel & lodging: $9,137Food & beverage: $8,628Consulting: $330Education: $215
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 143 | $64,921 |
| Vanda Pharmaceuticals Inc. | 34 | $1,299 |
| Alkermes, Inc. | 55 | $928 |
| Otsuka America Pharmaceutical, Inc. | 48 | $793 |
| Neurocrine BioSciences, Inc. | 30 | $637 |
| E.R. Squibb & Sons, L.L.C. | 34 | $616 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 31 | $467 |
| Lundbeck LLC | 15 | $252 |
| Janssen Pharmaceuticals, Inc | 12 | $223 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 4 | $169 |
Products named: UZEDY, AUSTEDO XR, HETLIOZ, INGREZZA, ARISTADA, COBENFY, REXULTI, CAPLYTA.
Industry payments across CA — which companies pay providers there.
